Last reviewed · How we verify
Enavogliflozin 0.3mg
Enavogliflozin 0.3mg is a Small molecule drug developed by Seoul St. Mary's Hospital. It is currently FDA-approved.
At a glance
| Generic name | Enavogliflozin 0.3mg |
|---|---|
| Sponsor | Seoul St. Mary's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy (PHASE4)
- To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
- Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy (PHASE4)
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults (PHASE1)
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients (PHASE3)
- Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enavogliflozin 0.3mg CI brief — competitive landscape report
- Enavogliflozin 0.3mg updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI
Frequently asked questions about Enavogliflozin 0.3mg
What is Enavogliflozin 0.3mg?
Enavogliflozin 0.3mg is a Small molecule drug developed by Seoul St. Mary's Hospital.
Who makes Enavogliflozin 0.3mg?
Enavogliflozin 0.3mg is developed and marketed by Seoul St. Mary's Hospital (see full Seoul St. Mary's Hospital pipeline at /company/seoul-st-mary-s-hospital).
What development phase is Enavogliflozin 0.3mg in?
Enavogliflozin 0.3mg is FDA-approved (marketed).
Related
- Manufacturer: Seoul St. Mary's Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing